Regeneron takes the long-haul approach to oncology, stumbles and all

Regeneron has conducted cutting-edge oncology research since checkpoint inhibitors were still the new kids on the block, and before blockbusters like Keytruda and Opdivo were even close to mainstream success. But despite massive scientific and financial achievement in other areas, Regeneron is still playing catch-up in cancer.